Purpose: This study aims to evaluate the association between composition of tumor-infiltrating lymphocytes (TIL) and expression of p16 in acral lentiginous melanoma (ALM), and their impact on prognosis. Materials and methods: A cohort of 148 surgical pathology specimens of ALM was studied. TIL were evaluated by immunohistochemical detection of CD3 and CD8, along with CD20, CD4, CD68, and CD163 in a subset of 43 cases. p16 protein expression was also investigated in all the cases. Results: The median age was 66 years, median Breslow thickness was 6.0 mm, grade III TIL was found in 28.4% and lymph nodes were involved in 54.2%. Breslow thickness (p < 0.001), stage I–II (p < 0.001), negative lymph nodes (p < 0.001) and < 10% p16 (p = 0.01) were associated with longer survival. Grade III of TIL was associated with thinner Breslow thickness (p = 0.008) and lower mitosis (p = 0.047). A higher density of CD3 TIL was associated with male gender (p = 0.008), thinner Breslow thickness (p = 0.047), negative lymph node (p = 0.031), early stage (p = 0.046), and p16 nuclear expression of > 10% (p = 0.045). Higher CD8 TIL was associated with > p16 (p = 0.03). Survival analysis found that longer survival had a trend to be associated with high TIL (p = 0.090). Levels of CD3+ and CD8+ cells were correlated with those of CD4+, CD20+, CD68+ and CD163+ immune cells. Conclusions: Higher levels of TIL tend to be associated with better overall survival in ALM. Loss of expression of p16 is associated with lower levels of CD3+ and CD8+ TIL, indicating a probable relationship between p16 and TIL immune response in ALM.
Bibliographical noteFunding Information:
This study was possible thanks to the use of the Automatic Multispectral Imaging System (Olympus BX63) financed by the Programa Nacional de Innovaci?n para la Competitividad y Productividad (Innovate Peru), under the contract 317-PNICP-EC-2014.
This study was possible thanks to the use of the Automatic Multispectral Imaging System (Olympus BX63) financed by the Programa Nacional de Innovación para la Competitividad y Productividad (Innovate Peru), under the contract 317-PNICP-EC-2014.
© 2019, Federación de Sociedades Españolas de Oncología (FESEO).
- Acral melanoma
- Prognosis Survival
- Tumor-infiltrating lymphocytes